Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 13 clinical trials
Featured trial
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement

urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received prior treatment.  

bladder cancer
urothelial carcinoma
metastatic urothelial carcinoma
bladder carcinoma
  • 320 views
  • 19 Dec, 2022
  • 64 locations
Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG)

uncontrolled cell growth and cancer. Patients with a greater than 25% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment

  • 18 views
  • 07 Feb, 2022
  • 13 locations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

neulasta
measurable disease
cytotoxic chemotherapy
palbociclib
selumetinib
  • 1032 views
  • 25 Oct, 2022
  • 108 locations
Study of Combined VisioCyt Test and FGFR3 Mutations on a Urinary Sample to Diagnose Bladder Tumors (URODX-FGFR3)

This study is a case-control, propsective and muticentric clinical trial, which aim to compare the specificity and sensibility of VisioCyt urinary cytological test combined with FGFR3 mutation

bladder tumor
FGFR3
  • 0 views
  • 26 Apr, 2022
  • 1 location
A Multicenter, Open-label Phase 1/2 Study of TYRA300 in Advanced Urothelial Carcinoma and Other Solid Tumors With Activating FGFR3 Gene Alterations (SURF301) (SURF301)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-300 in cancers with FGFR3 activating gene alterations

advanced urothelial carcinoma
FGFR3
measurable disease
metastatic urothelial carcinoma
  • 0 views
  • 21 Oct, 2022
  • 3 locations
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

Calmette-Guerin (BCG) or chemotherapy instilled into the bladder. Participants in this study will have bladder cancer with a mutation in the FGFR3 gene. FGFR3 mutations are the most common genetic

transurethral resection
mitomycin
neutrophil count
gemcitabine
intravesical chemotherapy
  • 0 views
  • 04 Oct, 2022
  • 7 locations
Infigratinib in Recurrent High-Grade Glioma Patients

This trial is an open-label, multicenter, Phase 0 trial that will enroll up to 20 participants with recurrent high-grade glioma with FGFR1 K656E or FGFR3 K650E mutation or FGFR3-TACC3

renal function test
contrast-enhanced magnetic resonance imaging
renal function
measurable disease
glioblastoma multiforme
  • 0 views
  • 28 Jan, 2021
  • 3 locations
A Phase II, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 Tablet in Adult Patients With Advanced Cholangiocarcinoma

This study is an open-label, multicenter study to evaluate the efficacy and safety of TT-00420 tablet in adult patients with advanced cholangiocarcinoma.

neutrophil count
measurable disease
  • 0 views
  • 22 Oct, 2022
  • 9 locations
  • 5 views
  • 15 Oct, 2022
  • 10 locations
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

, [111In]-FPI-1967, and vofatamab and the preliminary anti-tumour activity of [225Ac]-FPI-1966 in participants with FGFR3-expressing advanced, inoperable, metastatic, and/or recurrent solid tumours. Phase

growth factor
renal function
measurable disease
monoclonal antibodies
immunohistochemistry
  • 1 views
  • 04 Oct, 2022
  • 1 location